Home > Oncology > Upfront lenvatinib-everolimus combo promising in kidney cancer

Upfront lenvatinib-everolimus combo promising in kidney cancer

European Urology
Reuters Health - 28/05/2021 - First-line therapy with a combination of lenvatinib and everolimus had promising anticancer activity in patients with advanced non-clear-cell renal-cell carcinoma, with most patients seeing a decrease in tumor size and manageable side effects, in a phase-2 trial. Non-clear-cell renal-cell carcinoma (nccRCC) makes up about 20% of RCC cases. Lenvatinib, a multitargeted tyrosine-kinase inhibitor (TKI), in combination with everolimus, an mTOR inhibitor, is approved for the treatment of advanced RCC after one prior anti-angiogenic therapy. Dr. Thomas Hutson with Texas Oncology-Baylor Charles A. Sammons Cancer Center in Dallas and colleagues tested once-daily oral lenvatinib (18 mg) plus everolimus (5 mg) in 31 patients with unresectable advanced or metastatic nccRCC (20 papillary, nine chromophobe and two unclassified) and no prior anticancer therapy for advanced disease. Most patients were classified as intermediate or poor risk according t...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on